Horizon developing new CRISPR-based screening tech platform

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/daizuoxin)
(Image: Getty/daizuoxin)

Related tags: CRISPR, Horizon Discovery, Drug discovery

Horizon Discovery is collaborating with a global pharmaceutical company to develop and apply single cell RNAseq-linked pooled CRISPR screening.

The gene editing and gene modulation technology firm has entered into a collaboration with an unnamed global pharma partner to develop the research tool for target identification and validation.

The company will offer the tools to offer to any future partners as part of its research services offering.

Horizon will lead the development using “a key discovery paradigm of the pharma partner,”​ according to the company. It also will use acquired infrastructure and optimization data.

Terry Pizzie, CEO of Horizon Discovery said, “Pooled CRISPR-Cas9 knockout screens have rapidly become an important tool in novel drug target identification and validation.”

“The co-development of this tool with a major pharma partner provides a substantive advance to Horizon’s already world-leading screening capabilities, offering our customers cutting-edge solutions not available elsewhere,”​ Pizzie said in a press release.

Horizon in 2017 launched​ its CRISPR interference (CRISPRi) and CRISPR activation (CRISPRa) screening service.

Related topics: Preclinical Research, Preclinical

Related news

Show more

Related products

show more

Validating The Simoa Technology

Validating The Simoa Technology

Frontage Laboratories | 01-Oct-2019 | Technical / White Paper

Frontage is the first and only laboratory to validate Quanterix’ Simoa HD1 Analyzer for performing immunoassays. Most of the advanced instruments used...

Related suppliers

Follow us

Products

View more

Webinars